Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis

Local, National (Brazil), Multicentric, Open, Non-Controlled, Phase IV, Study of Lactoserum (Dermacyd Femina®), in Women at Reproductive Age, to Prevent Recurrence of Bacterial Vaginosis, During Three Months, After Standard Treatment With Metronidazole.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00556179

Enrollment

122

Registered

2007-11-09

Start date

2007-09-30

Completion date

Unknown

Last updated

2009-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial Vaginosis

Brief summary

The purpose of this study is to demonstrate if the use of Dermacyd can avoid the recurrence of bacterial vaginosis after three months of the standard treatment.

Interventions

DRUGLactoserum (Dermacyd Femina®)

Once a day during three months

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* Women in reproductive age * Confirmed cure of bacterial vaginosis after treatment with oral metronidazole. * Vaginal bacterioscopic examination negative for candida and trichomonas.

Exclusion criteria

* Pregnant or breastfeeding women * Allergy to dermacyd The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Design outcomes

Primary

Measure	Time frame
Rate of recurrence of bacterial vaginosis after three months of treatment.	Three months

Secondary

Measure	Time frame
Quality of life	Three months
Vaginal Candidiasis	Three months
AE, particularly genital irritation (tolerability use of dermacyd)	During the study

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026